logo-1000

MEET OUR TEAM

We are developing new pan-cancer therapeutics leveraging the ELANE pathway to selectively kill cancer cells. Our experienced team has carved a path over decades of academic and industry roles. We are motivated to confront unmet medical needs in the world with novel and compelling science.

Onchilles Team

COURT R. TURNER, JD

Cofounder and Chief Executive Officer

LEV BECKER, PhD

Cofounder and Chief Scientific Officer

Marc Nasoff, PhD

Chief Development Officer

Emily Roberts-Thomson

SVP, Development Operations

PETER HABERZ , PhD

Vice President, Corporate Development

CHANG CUI, PhD

Senior Scientist

RAVINDRA GUJAR, PhD

Senior Scientist

Carmen White

Senior Accountant

MARIA FUMAGALLI

Senior Research Associate

NICOLE MARTINEZ

Research Associate

Board Of Directors

KEVIN LI, PhD

LYZZ Capital

Mike Liang, PhD

InVivium Capital

Thomas DeSouza

Kennedy Lewis Investment Management

COURT R. TURNER, JD

Chair

LEV BECKER, PhD

Key Advisors

ALAIN ALGAZI, MD

Clinical Advisor

IGOR PUZANOV, MD, MSCI, FACP

Clinical Advisor

BRENDAN ECKELMAN, Ph.D.

Scientific Advisor

JEFFREY HAGER, PhD

Scientific Advisor

MITCHELL B. FRIEDMAN, PhD, DABT

Toxicology Advisor

DISCOVER YOUR PATH

Onchilles Pharma is looking for talented and
enthusiastic people to join our quest.

JOIN OUR QUEST!